Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - eptacog alfa (activated) 8mg;   - powder for injection with diluent - 8 mg - active: eptacog alfa (activated) 8mg   excipient: calcium chloride dihydrate glycylglycine mannitol methionine nitrogen polysorbate 80 sodium chloride sucrose histidine water for injection - indicated for the control of bleeding and surgical prophylaxis in patients: · with inhibitors to coagulation factors viii or ix · with congenital fvii deficiency · with glanzmann's thrombasthenia, who have antibodies to gpiib-iiia and/or hla, and with past or present refractoriness to platelet transfusions

Iisrael - inglise - Ministry of Health

novo nordisk ltd, israel - insulin aspart - suspension for injection - insulin aspart 100 iu/ml - insulin aspart - insulin aspart - treatment of diabetes mellitus.

Singapur - inglise - HSA (Health Sciences Authority)

novo nordisk pharma (singapore) pte ltd - insulin aspart - injection - 100 u/ml - insulin aspart 100 u/ml

Singapur - inglise - HSA (Health Sciences Authority)

novo nordisk pharma (singapore) pte ltd - insulin human, rdna - injection - 100iu/ml - insulin human, rdna 100iu/ml

Euroopa Liit - inglise - EMA (European Medicines Agency)

novo nordisk a/s - turoctocog alfa - hemophilia a - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). novoeight can be used for all age groups.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

novo nordisk - coagulation factor viia recombinant human (unii: ac71r787ov) (coagulation factor viia recombinant human - unii:ac71r787ov) - coagulation factor viia recombinant human 1 mg in 1 ml - novoseven rt, coagulation factor viia (recombinant), is indicated for: none known. risk summary there are no adequate and well-controlled studies using novoseven rt in pregnant women to determine whether there is a drug-associated risk. treatment of rats and rabbits with novoseven in reproduction studies has been associated with mortality at doses up to 6 mg per kg body weight and 5 mg per kg body weight respectively. at 6 mg per kg body weight in rats, the abortion rate was 0 out of 25 litters; in rabbits at 5 mg per kg body weight, the abortion rate was 2 out of 25 litters. twenty-three out of 25 female rats given 6 mg per kg body weight of novoseven gave birth successfully, however, two of the 23 litters died during the early period of lactation. no evidence of teratogenicity was observed after dosing with novoseven. in the u.s. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary there is

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, suspension - excipient ingredients: zinc; dibasic sodium phosphate dihydrate; protamine sulfate; metacresol; sodium chloride; sodium hydroxide; glycerol; phenol; hydrochloric acid; water for injections - treatment of diabetes mellitus.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, solution - excipient ingredients: phenol; sodium chloride; sodium hydroxide; water for injections; hydrochloric acid; zinc; metacresol; dibasic sodium phosphate dihydrate; glycerol - treatment of diabetes mellitus.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, solution - excipient ingredients: phenol; zinc; dibasic sodium phosphate dihydrate; sodium hydroxide; glycerol; metacresol; sodium chloride; water for injections; hydrochloric acid - treatment of diabetes mellitus.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, solution - excipient ingredients: water for injections; metacresol; glycerol; sodium chloride; dibasic sodium phosphate dihydrate; hydrochloric acid; sodium hydroxide; zinc; phenol - treatment of diabetes mellitus.